“…For example, [ 68 Ga]Ga-DOTA-TATE has been effectively employed for the diagnostic PET imaging of patients with neuroendocrine tumors receiving peptide receptor radiotherapy with [ 177 Lu]Lu-DOTA-TATE. 3,4 Likewise, [ 68 Ga]Ga-PSMA-617 has shown promise for the PET imaging of prostate cancer patients undergoing treatment with [ 177 Lu]Lu-PSMA-617 or [ 225 Ac]Ac-PSMA-617. [5][6][7][8] This approach is not limited to 68 Galabeled PET imaging agents, of course: several 89 Zr-labeled antibodies have also been used as companion imaging agents for radioimmunotherapeutics labeled with nuclides including yttrium-90, lutetium-177, and actinium-225.…”